Iopidine

Apraclonidine, the active ingredient in Iopidine, is an alpha‑2 adrenergic agonist presented as an ophthalmic solution for ocular (topical) use. It is employed to lower intra‑ocular pressure in patients with glaucoma or ocular hypertension.

GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Apraclonidine is used in ophthalmology to manage conditions associated with elevated intra‑ocular pressure.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Secondary glaucoma (e.g., steroid‑induced): helps control pressure when other agents are insufficient.

Topical apraclonidine may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Transient ocular burning or stinging - Conjunctival hyperemia - Mild eyelid edema - Blurred vision - Dry eye sensation

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis) - Significant hypotension (systemic absorption) - Corneal epithelial defects - Persistent ocular inflammation - Vision loss (rare)

Before prescribing apraclonidine eye drops, clinicians should consider the following precautions. - Avoid use in patients with known hypersensitivity to apraclonidine or any component of the formulation: discontinue immediately if reaction occurs. - Caution in patients with cardiovascular disease or low blood pressure: monitor systemic blood pressure. - Do not use concomitantly with other alpha‑2 agonists without medical supervision: risk of additive hypotensive effect. - Limit duration of therapy to the period required for pressure control: prolonged use may increase risk of adverse events. - Store below 25°C: keep in original container, protect from light and moisture.

Apraclonidine can interact with other ocular or systemic agents, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with other topical alpha‑2 agonists (e.g., brimonidine): may cause excessive ocular hypotension. - Systemic alpha‑blockers (e.g., prazosin): risk of additive systemic hypotension. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops (e.g., timolol): combined pressure‑lowering effect may be excessive; monitor IOP. - Topical corticosteroids: may mask signs of ocular inflammation; observe closely. - Systemic antihypertensives: monitor blood pressure for systemic absorption effects.